Top Markets
#1 Glidr Glidr +51.75%
#2 Akedo Akedo +51.75%
#3 DOVU DOVU +48.15%
#4 Black Phoenix Black Phoenix +34.08%
#5 Velvet Velvet +33.34%
#6 Cross Cross +29.27%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.47%
#8 OVERTAKE OVERTAKE +15.82%
#9 Bitway Bitway +15.10%
#10 QANplatform QANplatform +14.50%
Coin of the day
Glidr Glidr
Settings
Language
ENGLISH
Currency
USD
Theme
E-therapeutics Plc E-therapeutics Plc

E-therapeutics Plc

ETX
Rank in Stocks #38864
E-therapeutics Plc, established in 2001 and headquartered in London, UK, is a... E-therapeutics Plc, established in 2001 and headquartered in London, UK, is a drug discovery research company. It employs an advanced computational platform that conducts in silico screening to forecast compounds and biological targets capable of profoundly altering biological systems, drawing insights from its proprietary network models. Additionally, the firm is developing an RNA interference (RNAi) platform aimed at achieving highly specific gene silencing.
Share Price
$0.12246314
Last synced: 2024-05-08
Market Cap
$767.28K
Change (1 day)
1.50%
Change (1 year)
0.00%
Country
GB
Trade E-therapeutics Plc (ETX)

Category

Healthcare
P/E ratio for E-therapeutics Plc (ETX)
P/E ratio as of 2026 TTM: 0
According to E-therapeutics Plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for E-therapeutics Plc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.